An unexpected effect of 5-MCA-NAT in chick retinal development

International Journal of Developmental Neuroscience

Volumn 27, Issue 6, 2009, Pages 511-515

  Sampaio, Lucia de Fatima Sobral ^a  

^a FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

Luzindole; Melatonin; MT3; Neurodevelopment; QR2 physiology; Retina

Indexed keywords

5 METHOXYCARBONYLAMINO N ACETYLTRYPTAMINE; CYCLIC AMP; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; LUZINDOLE; MELATONIN; MELATONIN DERIVATIVE; MELATONIN RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CHICK; CONCENTRATION RESPONSE; CONTROLLED STUDY; INHIBITION KINETICS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; RETINA DEVELOPMENT; STIMULATION;

AGING; ANIMALS; BINDING SITES; CHICK EMBRYO; CHICKENS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; MELATONIN; NEUROGENESIS; NEURONS; ORGAN CULTURE TECHNIQUES; ORGANOGENESIS; QUINONE REDUCTASES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, MELATONIN; RETINA; SECOND MESSENGER SYSTEMS; TRYPTAMINES; UP-REGULATION;

EID: 68549118659     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2009.07.001     Document Type: Article

References (40)

1. Alarma-Estrany P., Crooke A., Peral A., and Pintor J. Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT. Autonomic Neuroscience 137 (2007) 63-66
2. Alarma-Estrany P., and Pintor J. Melatonin receptors in the eye: location, second messengers and role in ocular physiology. Pharmacology & Therapeutics 113 (2007) 507-522
3. Almeida-Paula L.D., Costa-Lotufo L.V., Ferreira Z.S., Monteiro A.E.G., Isoldi M.C., Godinho R.O., and Markus R.P. Melatonin modulates rat myotube-acetylcholine receptors by inhibiting calmodulin. European Journal of Pharmacology 525 (2005) 24-31
4. Boutin J.A., Marcheteau E., Hennig P., Moulharat N., Berger S., Delagrange P., Bouchet J.P., and Ferry G. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate. Journal of Pineal Research 45 (2008) 524-531
5. Buck J., Sinclair M.L., Schapal L., Cann M.J., and Levin L.R. Cytosolic adenylyl cyclase defines a unique signaling molecule in mammals. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 79-84
6. Buryanovskyy L., Fu Y., Boyd M., Ma Y., Hsieh T.C., Wu J.M., and Zhang Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 43 (2004) 11417-11426
7. Celli C.M., Tran N., Knox R., and Jaiswal A.K. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochemical Pharmacology 28 (2006) 366-376
8. Chomarat P., Cogé F., Guénin S.P., Mailliet F., Vella F., Mallet C., Giraudet S., Nagel N., Leonce S., Ferry G., Delagrange P., and Boutin J.A. Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference. Biochimie 89 (2007) 1264-1275
9. Delagrange P., and Boutin J.A. Therapeutic potential of melatonin ligands. Chronobiology International 23 (2006) 413-418
10. Dkhissi O., Chanut E., Versaux-Botteri C., Trouvin J.H., Repérant J., and Nguyen-Legros J. Day and night dysfunction in intraretinal melatonin and related indoleamines metabolism, correlated with the development of glaucoma-like disorder in an avian model. Journal of Neuroendocrinology 10 (1998) 863-869
11. Dubocovich M.L., Rivera-Bermudez M.A., Gerdin M.J., and Masana M.I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Frontiers of Biosciences 8 (2003) 1093-1108
12. Duncan J.S., Gyenis L., Lenehan J., Bretner M., Graves L.M., Haystead T.A., and Litchfield D.W. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Molecular & Cellular Proteomics 7 (2008) 1077-1088
13. El Halawani M.E., Kang S.W., Leclerc B., Kosonsiriluk S., and Chaiseha Y. Dopamine-melatonin neurons in the avian hypothalamus and their role as photoperiodic clocks. General and Comparative Endocrinology 163 (2009) 123-127
14. Horio B., Sears M., Mead A., Matsui H., and Bausher L. Regulation and bioelectrical effects of cyclic adenosine monophosphate production in the ciliary epithelial bilayer. Investigative & Ophthalmology Visual Science 37 (1996) 607-612
15. Iuvone P.M. Development of melatonin synthesis in chicken retina: regulation of serotonin N-acetyltransferase activity by light, circadian oscillators, and cyclic AMP. Journal of Neurochemistry 54 (1990) 1562-1568
16. Iuvone P.M., and Gan J. Melatonin receptor-mediated inhibition of cAMP accumulation in chick retinal cell cultures. Journal of Neurochemistry 63 (1994) 118-124
17. Jockers R., Maurice P., Boutin J.A., and Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?. British Journal of Pharmacology 154 (2008) 1182-1195
18. Litvin T.N., Kamenetsky M., Zarifyan A., Buck J., and Levin L.R. Kinetic properties of "soluble" adenylyl cyclase. Synergism between calcium and bicarbonate. Journal of Biological Chemistry 278 (2003) 15922-15926
19. Long II D.J., Iskander K., Gaikwad A., Arin M., Roop D.R., Knox R., Barrios R., and Jaiswal A.K. Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. Journal of Biological Chemistry 277 (2002) 46131-46139
20. Lotufo C.M., Lopes C., Dubocovich M.L., Farsky S.H., and Markus R.P. Melatonin and N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation. European Journal of Pharmacology 430 (2001) 351-357
21. Lundmark P.O., Pandi-Perumal S.R., Srinivasan V., Cardinali D.P., and Rosenstein R.E. Melatonin in the eye: implications for glaucoma. Experimental Eye Research 84 (2007) 1021-1030
22. Mailliet F., Ferry G., Vella F., Thiam K., Delagrange P., and Boutin J.A. Organs from mice delected for NRH: quinone oxidoreductase 2 are deprived of the melatonin site MT3. FEBS Letters 578 (2004) 116-120
23. Mailliet F., Ferry G., Vella F., Berger S., Cogé F., Chomarat P., Mallet C., Guénin S.P., Guillaumet G., Viaud-Massuard M.C., Yous S., Delagrange P., and Boutin J.A. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochemical Pharmacology 19 (2005) 74-88
24. Molinari E.J., North P.C., and Dubocovich M.L. 2-[125I] iodo-5-methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites. European Journal of Pharmacology 22 (1996) 159-168
25. Moreno M.C., Campanelli J., Sande P., Sanez D.A., Keller Sarmiento M.I., and Rosenstein R.E. Retinal oxidative stress induced by high intraocular pressure. Free Radical Biology and Medicine 15 (2004) 803-812
26. Nosjean O., Ferro M., Cogé F., Beauverger P., Henlin J.M., Lefoulon F., Fauchère J.L., Delagrange P., Canet E., and Boutin J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. Journal of Biological Chemistry 275 (2000) 31311-31317
27. Nosjean O., Nicolas J.-P., Klupsch F., Delagrange P., Canet E., and Boutin J.A. Comparative pharmacological studies of melatonin receptors: MT1, MT2 e MT3/QR2. Biochemical Pharmacology 61 (2001) 1369-1379
28. Natesan A.K., and Cassone V.M. Melatonin receptor localization and rhythmcity in the retina of the domestic chick, Gallus domesticus. Visual Neuroscience 19 (2002) 265-274
29. Paes-de-Carvalho R. Adenosine as a signaling molecule in the retina: biochemical and developmental aspects. Anais da Academia Brasileira de Ciências 74 (2002) 437-451
30. 3 receptors in the regulation of intraocular pressure in rabbits. European Journal of Pharmacolology 416 (2001) 251-254
31. Rada J.A.S., and Wiechmann A.F. Melatonin receptors in chick ocular tissues: implications for a role of melatonin in ocular growth regulation. Investigative & Ophthalmology Visual Science 47 (2006) 25-33
32. Reis R.A., Ventura A.L., Kubrusly R.C., de Mello M.C., and de Mello F.G. Dopaminergic signalling in the developing retina. Brain Research Review 54 (2007) 181-188
33. Sampaio L.F.S., and Paes-de-Carvalho R. Developmental regulation of group III metabotropic glutamate receptors modulating adenylate cyclase activity in the avian retina. Neurochemistry International 33 (1998) 367-374
34. Sampaio L.F.S., Hamassaki-Britto D.E., and Markus R.P. Influence of melatonin on the development of functional nicotinic acetylcholine receptors in cultures chick retinal cells. Brazilian Journal of Medical and Biological Research 38 (2005) 603-613
35. Sampaio L.F.S. Melatonin inhibitory effect on cAMP accumulation in the chick retina development. International Journal of Developmental Neuroscience 26 (2008) 277-282
36. Santos R.C., and Araujo E.G. Cyclic AMP increases the survival of ganglion cells in mixed retinal cell cultures in the absence of exogenous neurotrophic molecules, an effect that involves cholinergic activity. Brazilian Journal of Medical and Biological Research 34 (2001) 1585-1593
37. Serle J.B., Wang R.F., Peterson W.M., Plourde R., and Yerxa B.R. Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. Journal of Glaucoma 13 (2004) 385-388
38. Schuster C., Williams L.M., Morris A., Morgan P.J., and Barrett P. The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. Journal of Neuroendocrinology 17 (2005) 170-178
39. Siu A.W., Maldonado M., Sanchez-Hidalgo M., Tan D.X., and Reiter R.J. Protective effects of melatonin in experimental free radical-related ocular diseases. Journal of Pineal Research 40 (2006) 101-109
40. Vella F., Ferry G., Delagrange P., and Boutin J.A. NRH: quinone reductase 2: an enzyme of surprises and mysteries. Biochemical Pharmacology 71 (2005) 1-12